@article{fdi:010067708,
  title = {{P}otential market size and impact of hepatitis {C} treatment in low- and middle-income countries},
  author = {{W}oode, {M}. {E}. and {A}bu-{Z}aineh, {M}. and {P}erriens, {J}. and {R}enaud, {F}. and {W}iktor, {S}. and {M}oatti, {J}ean-{P}aul},
  editor = {},
  language = {{ENG}},
  abstract = {{T}he introduction of direct-acting antiviral agents ({DAA}s) has made hepatitis {C} infection curable in the vast majority of cases and the elimination of the infection possible. {A}lthough initially too costly for large-scale use, recent reductions in {DAA} prices in some low-and middle-income countries ({L}a{MIC}s) has improved the prospect of many people having access to these drugs/medications in the future. {T}his article assesses the pricing and financing conditions under which the uptake of {DAA}s can increase to the point where the elimination of the disease in {L}a{MIC}s is feasible. {A} {M}arkov simulation model is used to study the dynamics of the infection with the introduction of treatment over a 10-year period. {T}he impact on {HCV}-related mortality and {HCV} incidence is assessed under different financing scenarios assuming that the cost of the drugs is completely paid for out-of-pocket or reduced through either subsidy or drug price decreases. {I}t is also assessed under different diagnostic and service delivery capacity scenarios separately for low-income ({LIC}), lower-middle-income ({LMIC}) and upper-middle-income countries ({UMIC}). {M}onte {C}arlo simulations are used for sensitivity analyses. {A}t a price of {US}$ 1680 per 12-week treatment duration (based on negotiated {E}gyptian prices for an all oral two-{DAA} regimen), most of the people infected in {LIC}s and {LMIC}s would have limited access to treatment without subsidy or significant drug price decreases. {H}owever, people in {UMIC}s would be able to access it even in the absence of a subsidy. {F}or {HCV} treatment to have a significant impact on mortality and incidence, a significant scaling-up of diagnostic and service delivery capacity for {HCV} infection is needed.},
  keywords = {developing countries ; direct-acting antiviral agents ({DAA}) ; hepatitis {C} ; markov simulation ; universal access ; {PAYS} {EN} {DEVELOPPEMENT}},
  booktitle = {},
  journal = {{J}ournal of {V}iral {H}epatitis},
  volume = {23},
  numero = {7},
  pages = {522--534},
  ISSN = {1352-0504},
  year = {2016},
  DOI = {10.1111/jvh.12516},
  URL = {https://www.documentation.ird.fr/hor/fdi:010067708},
}